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Edited by Horst FeldmannAbstract The synergy between experimental and computational
biology has greatly beneﬁted both ﬁelds, providing invaluable
information in many diﬀerent areas of the life sciences. This
minireview will focus on one speciﬁc aspect of computational
biology, molecular modelling, and describe a few examples high-
lighting the eﬀectiveness of protein structural analysis and mod-
elling in providing relevant information about systems of
biomedical interest.
 2006 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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There is no question that the dawn of the Human Genome
Project has been one of the most important investments by
governments and companies in life sciences [1–3]. This has
been followed by investments in projects aimed at mapping
and sequencing of genomes of other species and phyla such
as the chimp, mouse, rat, maize, soy and more. The genome
projects have catalysed other investments in biotechnology
and an increased attention to bioinformatics, the discipline
arising from the marriage of biology and computer sciences,
one of the fastest growing ﬁelds in science. It is only fair at this
stage to ask whether this is having a positive impact on the
well-being of our species and to which extent it is having an ef-
fect on human health. I am often asked the question: ‘‘But, at
the end, how many of the available drugs were discovered
thanks to computational biology, modelling and drug design?’’
Clearly the question cannot just refer to drugs discovered
‘‘solely’’ through computation, because at least the ﬁnal test
has to be performed in the laboratory or in the clinical, how-
ever it is clear that computation can contribute to diﬀerent ex-
tent to a drug discovery process.
One can take a broad view and include cases where a phar-
maceutical target has been discovered through computational
analysis of available data, even if the ﬁnal development of
the therapeutic agent has been mostly achieved through exper-
imental screening or where the initial lead compound has been
discovered experimentally and reﬁned later with computa-
tional methods. In this perspective, it is fair to state that essen-*Fax: +39 06 4453933.
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category.
In this review, I will limit myself to discuss a few examples to
illustrate the power of the combined experimental and compu-
tational approaches. I will show how modelling can be
exploited to discover a pharmaceutical target (Example I: lep-
tin and its receptor), to develop novel therapeutics agent
(Example II: engineered antibodies) and to develop novel mol-
ecules for immunological purposes (Example III: HCV enve-
lope glycoprotein) although there are many more examples
that could have been selected such as the discovery process
of drugs against HIV protease, glycogen phosphorylase,
kinases, G-protein coupled receptors and more which are
described in several excellent reviews [4–13].
First, let me brieﬂy summarize the rational basis of the dif-
ferent computational protein modelling methods.2. Protein structure prediction
Available methods for predicting the three-dimensional
structure of a protein, which is in turn the main determinant
of its biological function, cannot only rely on our understand-
ing of the basic laws of physics, because of the enormous com-
plexity of a protein structure. The structure of a protein is
formed by hundreds to thousand of atoms, but the resulting
conformation is only marginally stable and held together by
a large number of very weak non-covalent interactions. The
accurate calculation of the relevant energy terms is far from
our reach at present, and all our approximations are too crude
to allow the precise conformation of the protein to be com-
puted. We therefore need to rely on empirical methods for
the prediction of a protein structure, which are, by and large,
based on principles that have been derived from the analysis of
known protein structures, namely:
 During evolution proteins tend to preserve their structure
[14].
 Diﬀerent proteins, even when no evolutionary relationship
can be detected from their sequence comparison, can have
a similar structure [15,16].
 Proteins are generally made up by similar local sub-struc-
tures [17].
The ﬁrst principle allows the structure of a protein to be pre-
dicted on the basis of the knowledge of the structure of an evo-
lutionarily related protein (comparative or homology
modelling) [18]. When this is not the case, methods known
as ‘‘fold recognition methods’’ are used to identify proteins
sharing a structural similarity with the target protein on theblished by Elsevier B.V. All rights reserved.
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words, these methods try to build a model of the target protein
‘‘as if’’ it had the structure of each and every protein in the
structure database and subsequently to evaluate the likelihood
of the resulting models. The recurrence of structural motifs can
be exploited by ‘‘fragment based methods’’ [21,22], the most
popular being Rosetta [21]. The strategy consists in building
many alternative conformations of the target protein using dif-
ferent combination of recurrent motifs and selecting the ‘‘best’’
model by optimising a sequence-structure ﬁtness function, sim-
ilarly to what is done in fold recognition.Fig. 1. The three dimensional structure of leptin [51]. PDB [52] code:
1AX8.3. Example I: leptin and its receptor
Since the early ﬁfties it became clear that body weight is reg-
ulated via a centrally acting signal that controls food intake
and energy expenditure. Indeed, if the blood systems of two
mice are joined, overfeeding one leads to decreased food intake
in the other [23].
One of the molecular players of the system was found to be
the ob gene: a mutation in this gene was identiﬁed in an obese
mouse strain [24]. The sequence of the gene, and of the corre-
sponding protein, was determined in 1994 and the protein was
called ‘‘leptin’’, from the Greek ‘‘leptos’’ (‘‘thin’’) [25].
Comparative modelling could not be used to assign a struc-
ture, and eventually a function, to the protein. No protein of
known structure shared a sequence similarity with leptin suﬃ-
ciently high to indicate a common evolutionary origin.
Fold recognition methods had been recently developed and
had started demonstrating their power in the ‘‘critical assess-
ment of techniques for protein structure prediction’’ (CASP)
experiment [26]. The latter is a blind assessment of methods
for protein structure predictions where computational biolo-
gists are requested to propose structural models for proteins
of unknown structure that are about to be solved experimen-
tally.
Steve Bryant and colleagues used their fold recognition
method for the leptin sequence and found that the ob sequence
is compatible with the structure of proteins belonging to the
family of helical cytokines [27]. Cytochines are proteins that
regulate the immune response by transmitting signals between
cells, are able to act at low concentration and bind with high
aﬃnity to a receptor. The biological mechanism of cytochines
was deﬁnitely compatible with a signal transmitter such as lep-
tin. Subsequently, the structural determination demonstrated
that the fold recognition hypothesis was correct (Fig. 1). Fur-
thermore, it was later demonstrated that leptin plays an impor-
tant role in the modulation of immune response and
inﬂammation, similarly to cytokines. However, the obese
mouse, so useful for identifying leptin, is not a good general
model for human obesity. The ob mouse has a non-functional
leptin, while in a number of cases obese humans do not have a
mutated leptin, rather they have levels 20–30 times higher than
those found in lean people. On the other hand, the structural
prediction results could be exploited further: if leptin resembles
cytokines, then it might act through a similar receptor and it
might be the receptor that carries a mutation in obese humans.
The leptin receptor was indeed identiﬁed in 1995 [28]. Espe-
cially after clinical trials on recombinant leptin were stopped
due to lack of eﬃcacy, the receptor has become an important
target in the therapy of obesity.4. Example II: engineered antibodies
An antibody is ideal for drug therapy because of its speciﬁc-
ity and plasticity. Antibodies can be thought of as Y-shaped
proteins consisting of four polypeptide chains: two identical
light chains, residing in the arms of the Y, and two identical
longer heavy chains, extending the length of the Y. Each of
the arms of the Y (known as a Fab fragment, for antigen bind-
ing) recognizes the antibody’s target, the molecule against
which the antibody is directed. The target is also referred to
as the antigen. Both antibody chains are composed of variants
of a basic domain of about 100 residues in length. The light
chain is formed by two of these domains, called the variable
domain (VL) and the constant domain (CL), based on the var-
iability in the amino acid sequence. The heavy chains contain a
variable domain (VH) and three constant domains (CH1,
CH2, CH3, and CH4). Each domain is formed by two b-sheets
packed face to face, linked together by a conserved disulphide
bridge, and by inter-strand loops (Fig. 2). This modular nature
and the separation of antibody functions make antibody
molecules particularly suitable candidates to be modiﬁed by
protein engineering.
The antigen binding sites of most antibodies are formed pri-
marily by six loops, three from the VL domain (L1, L2, and
L3) and three from the VH domain (H1, H2, and H3). The re-
gions of the variable domains outside these loops are called the
framework.
Two main strategies have been used to engineer antibody
molecules:
 Generation of large collections of antibodies with diﬀerent
speciﬁcity (e.g., from phage-display libraries) and selection
based on, for example, speciﬁc antigen-binding activity,
high level expression, expression in speciﬁc cellular environ-
ments, etc. [29].
Fig. 2. The structure of a monoclonal antibody [53]. PDB code: 1IGT.
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tion of antibody structures, through the use of modelling
techniques, to endow them with new properties (e.g., im-
proved stability or aﬃnity for the antigen). This procedure
is also used to improve antibodies selected by the ﬁrst strat-
egy [30].
Successful examples of antibody design include the design of
smaller antibody fragments still able to bind the antigen, fu-
sion proteins, modiﬁcations of the antigen binding site and
humanization of antibodies.
As antibodies are very large molecules, the use of small frag-
ments can be advantageous for both research and in vivo
applications, due, for example, to their increased ability to
penetrate tissues and to their faster clearance from tissues
and serum. Antibody fragments can be joined to fragments
coming from diﬀerent proteins and bearing speciﬁc activities
(e.g., toxins, enzymes, and ligands) to deliver them to speciﬁc
cellular targets. Modiﬁcations of the antigen binding site are
aimed, for example at increasing the aﬃnity or speciﬁcity
toward a speciﬁc antigen or at introducing novel functions.
Finally, one of the most widely used and successful modiﬁca-
tions of antibodies is the humanisation of animal-derived
antibodies, aimed at reducing their immunogenicity for
serotherapy in humans. All these approaches take advantage
of our ability to model the structure of antibodies from their
sequences.In known immunoglobulins, the framework regions are
highly conserved in both sequence and main-chain conforma-
tion, and they can be accurately predicted using standard
homology modelling techniques [31]. Thanks to the presence
of conserved residues at the interface between the variable do-
mains of the light and of the heavy chain (VL and VH), the rel-
ative geometry of these domains is also conserved, creating a
scaﬀolding of relatively conserved structure on which the anti-
gen binding site is erected.
The six loops of the antigen binding site are more variable
in sequence than the rest of the variable domains. Based on
this observation, Kabat and co-workers [32] correctly pre-
dicted that these hypervariable regions were involved in anti-
gen binding, and called them ‘‘complementarity determining
regions’’ or CDRs. This sequence-based deﬁnition is largely
overlapping with the structural deﬁnition subsequently pro-
vided by Chothia and Lesk [33], who include in the antigen
binding loops only those residues which are not part of the
conserved b-sheet framework. Chothia and Lesk showed that,
in spite of their high sequence variability, ﬁve of the six loops
of the antigen binding site can assume just a small repertoire
of main chain conformations, called ‘‘canonical structures’’
[33]. These conformations are determined by the length of
the loops and by the presence of key-residues at speciﬁc posi-
tions in the antibody sequence – either within the loops or in
the framework regions – through their packing, hydrogen
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mations. On the other hand, the other loop residues are free
to vary to modify the topography and chemical–physical
properties of the antigen binding site.
The speciﬁc pattern of residues that determine each canoni-
cal structure forms a ‘‘signature’’ whereby a canonical struc-
ture can be recognised in the sequences of an
immunoglobulin of unknown structure, and can therefore be
predicted based on the antibody sequence alone. This has been
demonstrated by the successful prediction of antibody struc-
tures in ‘‘blind tests’’, where the conformation of the loops
was correctly predicted before the experimental structure was
published [34,35]. The accuracy of the predicted conformations
was very high. The relative positions of these loops are also
predicted with good accuracy if framework structures with
high sequence similarity are used as a template to model the
target antibody. The H3 loop is a special case and a relation-
ship between its sequence and structure could only be estab-
lished between the main chain conformation of the 10
residues of the loop proximal to the framework (the ‘‘torso’’
of the loop) and the sequence of the antibody. Speciﬁc data-
base search procedures can be used to predict the main chain
conformation of the head regions in many cases [36].
Taken together, the above observations mean that, given an
unknown antibody sequence, there is a high probability that
the hypervariable loops L1, L2, L3, H1, and H2 have a main
chain conformation that corresponds to a known canonical
structure, and that the torso region of H3 has a conformation
that corresponds to one of the conformations observed in
known structures and predictable from sequence. Conse-
quently, except for the head region of some H3 loops, very
accurate 3D models can be built for most antibodies.
The identiﬁcation of the determinants of the antigen binding
loop conformation is a necessary requirement for the success-
ful engineering of antibodies with prescribed speciﬁcity. In any
design involving modiﬁcations and/or transplant of the antigen
binding site loops (aimed, for example, at varying the antibody
aﬃnity or speciﬁcity towards the antigen, at the introduction
of a metal binding site, or at the generation of large repertoires
of antibody molecules through the use of libraries) it is indeed
necessary to keep into account that mutations of residues at
most positions of the hypervariable loops will determine only
local variations of the antigen-binding site, due to the size
and chemical–physical properties of the mutated side-chains,
leaving the main-chain conformation of the hypervariable
loops unchanged. On the other hand, mutations at key-sites
will, in most cases, also aﬀect the main chain conformation
of the antigen binding site loops. This second modiﬁcation
is likely to have a larger impact on the aﬃnity toward the
antigen.
The technique of antibody ‘‘humanization’’ was developed
by Greg Winter and colleagues at the University of Cambridge
[37]. The basic idea is to obtain a mouse antibody able to bind
a speciﬁc target and transplant only those parts of a mouse
antibody directly involved in binding to a human antibody
and not aﬀecting the main-chain conformation of the antigen
biding loops. This might require the modiﬁcation of amino
acids that are not part of the antigen binding site. Ideally, an
optimal humanized antibody should contain the fewest num-
ber of mouse amino acids required to retain the speciﬁcity of
the mouse antibody, therefore successful design requires to rely
on our understanding of the relationship between the sequenceand structure of the antigen binding sites [38]. A large number
of humanized antibodies are already on the market and many
are currently in clinical trials worldwide [39].5. Example III: HCV envelope glycoprotein
Chronic Hepatitis C aﬀects more than 200 million people in
the world, approximately 80% of patients develop chronic hep-
atitis, and 20% of these progress onto liver cirrhosis and hepa-
tocellular carcinoma [40].
The etiological agent is a virus, called HCV, an RNA virus
with a genome containing a single open reading frame that en-
codes a polyprotein of about 3000 amino acids.
Polyprotein processing occurs via a combination of host and
viral proteinases and this gives at least 10 unique proteins: C,
E1, E2, p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B. C, E1,
and E2 form the structural components of the virus, the other
proteins have enzymatic activities [41].
Similarly to all RNA viruses, HCV has a high mutation rate
(approximately one nucleotide change per genome per genera-
tion) and exists as a quasi specie and therefore emergence of
resistance is one of the major problems to be faced in the devel-
opment of drugs and vaccines against the virus.
Chimpanzees immunized with puriﬁed recombinant envelope
glycoproteins (E1 and E2) have been shown to be protected
against challenge with homologous virus [42], i.e. with a virus
containing the exact same E1/E2 sequence, suggesting that
these proteins are the ideal targets for vaccine development.
There is no experimental structural information on E2, and,
at the beginning of the 1990s, no sequence similarity with any
other protein could be detected. Only in 1995 the sequence of
two viruses related to HCV was obtained by inoculating tam-
arin monkeys with serum from GB, a surgeon suﬀering from
acute hepatitis. The sequences of these viruses, designated
GB viruses A and B were used as probes for screening infected
individuals: an individual with hepatitis found in West Africa
was demonstrated to be infected with a virus similar to GBV-A
and GBV-B [43]. Interestingly, GBV-A was later found in sev-
eral species of New World monkeys. Most likely GBV-A and
GBV-B did not originate from the initial GB inoculum and
were probably present in tamarins before the inoculum.
In HCV infected patients, a strong humoral immune re-
sponse is frequently observed, although it is rarely suﬃcient
to block the virus. Neutralizing B-cell epitopes have been
mapped to a hypervariable region (HVR1) at the N-terminus
of the E2 envelope protein [44]. Unfortunately viral resistance
mutants evolve rapidly during infection. This variability of
HCV, much of which concentrated in the HVR1 region, sug-
gested that a more successful vaccine design might require the
induction of a broader, more cross-reactive response targeting
many HVR1 simultaneously. Puntoriero et al. have ap-
proached this problem using a combination of bioinformatics
and experimental methods [45]. Sequence variation within
HVR1 was analysed to derive a degenerate consensus sequence
accounting for80% of the total sequence variability. A library
of synthetic HVR1 sequences representing the degenerate con-
sensus (mimotopes) was then displayed on bacteriophage M13
and sera from HCV infected patients were used to select HVR1
mimotopes with the highest cross-reactivity. Sequence analysis
combined with mutagenesis experiments allowed identiﬁcation
of positions within HVR1 that aﬀect cross-reactivity.
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deed induced antibodies that recognized a broad range of nat-
ural HVR1 variants, as peptides or in context of a recombinant
E2 protein. More importantly it was shown that administra-
tion of a pool of mimotopes signiﬁcantly increased the overall
immune response against natural HVR1 sequences. A similar
strategy is now being explored for other infectious diseases
to solve the problem of the emergence of escape mutants.
It should also be mentioned that fold recognition techniques
were used to predict the structure of the E2 glycoprotein, taking
advantage of the availability of the HCV related sequences de-
scribed before and of experimental data on the location of
known epitopes, potential N-glycosylation sites and receptor
binding [46]. The ﬁnal model for HCV E2 (Fig. 3) was based
on the Flaviviral envelope protein E of Tick Borne Encephalitis
virus (TBEV). The model also predicted the presence of a spe-
ciﬁc heparin-binding domain, subsequently experimentally ver-
iﬁed. TBEV belongs to the Flaviviridae family, the same family
to which HCV belongs. A corollary of the modelling results is
therefore that these viruses are all evolutionarily related. This
was later conﬁrmed by the crystal structure determination of
the E2 protein of a member of a diﬀerent family (alpha), Sem-
liki Forest Virus (SFV). Quite unexpectedly, the SFV E1 mono-
mer structure closely resembles the TBEV E structure [47]. This
new data therefore retrospectively justiﬁes the choice of TBEV
E as a structural template for HCV E2.
Given the diﬃculty in obtaining the experimental structure
of this protein, the model is being used by several groups as
a framework for designing experiments [41]. There is also some
hope that the detected evolutionary relationship between HCV
and other ﬂaviridae and alphaviridae can be further exploited
for studying and understanding the infection mechanism of
HCV.6. Conclusions
The knowledge, even approximate, of the three-dimensional
structure of a protein is essential for understanding the details
of its molecular function and gives valuable insights for the
development of eﬀective rational strategies for experimentsFig. 3. The model for a homodimeric HCV E2 gsuch as studies of disease related mutations, site directed muta-
genesis, or structure based drug design.
The examples described here cover only a very tiny fraction
of the results that are continuously being produced by the
computational biologists taking advantage of the data made
available and of sophisticated data analysis techniques. It
should also be mentioned that, in several cases, the original
project was not directly aimed at developing novel therapies,
but rather at gaining some basic understanding of the biolog-
ical system. This strongly suggests that a careful and thorough
analysis of biological data, through the power of computa-
tional biology, cannot but lead to the development of novel
therapeutical strategies.
Structure prediction methods are continuously being devel-
oped and evaluated and they can greatly accelerate the discov-
ery process and provide a structural framework for new
hypotheses. Clearly, diﬀerent methods have diﬀerent reliability
and this has to be taken into account when using their results.
The only way to evaluate the eﬃcacy of a prediction method is,
of course, to compare the prediction with an experimental re-
sult. However this creates many problems. Most of the predic-
tion methods are heuristic, that is are based on statistical
observations of known protein structures, so that somehow
information on already known protein structures is contained
in the method itself and it is possible that the method will per-
form better on already known protein structures than in real
cases, when it is applied to protein of unknown structure. This
problem is not trivial and has been addressed (and reasonably
satisfactorily solved) by the worldwide CASP experiment men-
tioned before [26]. In this experiment methods are tested on
proteins of unknown structure, but whose structures will be
available in a reasonably short time. The results are discussed
in a meeting where assessors and predictors convene and the
conclusions are made available to the whole scientiﬁc commu-
nity via the World Wide Web and scientiﬁc publications.
For methods that can be run automatically, there are auto-
matic systems that collect the results of diﬀerent methods as
soon as a new protein structure is determined, and therefore be-
fore any method had a chance to use it in the training set [48–
50]. The results of CASP and of the automatic testing servers
are publicly available via Internet and they represent extremelylycoprotein. PMDB [54] code: PM0074602.
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tion method.
Finally, there is no doubt that the most useful models are
those originated by a synergy between computational and
experimental eﬀorts, where the models are used to design
experiments the results of which are used to validate and reﬁne
the model.
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